Kiat Ruxrungtham - Concepedia

Author

Kiat Ruxrungtham

Also Known As

A Avihingsanon, Angele Gayet-Ageron, B. Clotet, Chureeratana Bowonwattanuwong, David Burger, Drew Weissman, Hai Long, Ines Otegui, Jintanat Ananworanich, K Ruxrungtham

495

Publications

14.5K

Citations

H-Index

189

Concepts

All Affiliations

Chulalongkorn University HIV Netherlands Australia Thailand Research Collaboration UNSW Sydney National Centre for Clinical Research on Emerging Drugs Mahidol University

About

Kiat Ruxrungtham is an author at Chulalongkorn University specializing in medicine, hiv, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	35	65	4.6K
2	Public Health	12	15	977
3	Social Sciences	3	3	156
4	Engineering	1	1	89
5	Health Sciences	1	1	17

Kiat Ruxrungtham

216

Publications

12K

Citations

H-Index

Page 1

	Year	Citations
Plasma Levels of Soluble CD14 Independently Predict Mortality in HIV Infection Netanya G. Sandler, Handan Wand, Annelys Roque, The Journal of Infectious Diseases	2011	1.1K
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study Frank van Leth, Praphan Phanuphak, Kiat Ruxrungtham, The Lancet Treatment And PreventionMedicineFirst-line Antiretroviral TherapyClinical TrialsAntiviral Drug Development	2004	683
Comprehensive serological profiling of human populations using a synthetic human virome George Xu, Tomasz Kula, Qikai Xu, Science Genetic TestingMolecular EpidemiologyViral DiagnosticsGenetic EpidemiologyImmunology	2015	487
Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial Calvin Cohen, Jaime Andrade‐Villanueva, Bonaventura Clotet, The Lancet Treatment And PreventionMedicineHuman RetrovirusClinical TrialsRilpivirine Versus Efavirenz	2011	369
Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial José Valdez Madruga, Daniel Berger, Marilyn McMurchie, The Lancet Treatment And PreventionAntiviral Drug DevelopmentAntiviral TherapyVirologyAntiviral Drug	2007	330
Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study John Gregson, Michele W. Tang, Nicaise Ndembi, The Lancet Infectious Diseases	2016	274
Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis Anthony Mills, Mark Nelson, Dushyantha Jayaweera, AIDS	2009	265
CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial Jintanat Ananworanich, Angèle Gayet‐Ageron, Michelle Le Braz, The Lancet Hiv/aids CounsellingContinuous TherapyTreatment And PreventionAntiviral TherapyTreatment Option	2006	240
Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort W. Phillip Law, Chris Duncombe, Apicha Mahanontharit, AIDS	2004	155
Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent Jing Yuan, Sheng Guo, David B. Hall, AIDS	2011	152

Page 1